FDA orders consumer medication guides for stimulants
The Carlat Psychiatry Report, Volume 5, Number 5, May 2007
James Ellison, MD, MPH
On February 21, 2007, the FDA directed all manufacturers of stimulants to develop Medication Guides for patients, spelling out, in non-technical language, the dangers of taking these medications.
James Ellison, MD
Clinical Director, Geriatric Psychiatry Program, McLean Hospital Associate Professor of Psychiatry, Harvard Medical School
Dr. Ellison has disclosed that he is on the speaker’s bureaus of Pfizer, Inc., Wyeth, Inc., and Forest Laboratories, and has spoken about Aricept, Effexor XR, Lexapro, and Namenda. He has received between $5,000 and $20,000 over the last 12 months for these activities. He has also received research grant support, via McLean hospital, from GlaxoSmithKline for research on Avandia (rosiglitazone). Dr. Carlat has reviewed and edited the content of this interview to ensure a balanced and unbiased presentation.